Taskin BioRegeneration, as one of the pioneers in the field of cell therapy, had an active and impactful presence at the 14th Congress of the Hematopoietic Stem Cell Transplantation Scientific Association, alongside the First National Hematology Congress of Iran, held from March 8 to 10, 2025, at the Tehran Heart Center.
The primary objective of Taskin’s participation was to introduce “DestroCell,” the first allogeneic cell therapy product in Iran approved for the treatment of GvHD patients. This innovative product, developed in line with the country’s scientific and therapeutic advancements, was presented at the congress as a new and effective solution for patient treatment.
Participation in this event not only provided an excellent opportunity to introduce DestroCell to the medical community but also strengthened existing collaborations and fostered new connections with physicians, hospitals, and other healthcare institutions. The scientific atmosphere and fruitful interactions at the congress created a platform for sharing knowledge and experiences among specialists and had a significant impact on expanding Taskin’s collaborations in the field of cell therapy.